Bevacizumab In The Treatment Of Ovarian Cancer Are Reviewed

Ovarian cancer‵s mortality rates are still the highes in the gynecologymalignant tumor, the malignant degree is high, the prognosis is poor.Nowthe main treatment is surgery,and postoperative chemotherapy.Nowtreatment regimen is given priority to with platinum-and paclitaxel-inovarian cancer.The5-year survival rate was still hovering in30-40%.So anemphasis of obstetrics and gynecology scholars all over the world has beenplaced on exploring a new cytotoxic drug for treatment of the disease.Currently, bevacizumab caused extensive concern of researchers ofOb-gyn.Bevacizumb is a recombinant human monoclonal antibody to theVEGF, neutralising the biological activity of VEGF inhibits the formationof new tumour vessels, causing regression of the remaining tumourvasculature. This slows tumour growth and metastasis.1-3In this article thecurrent ways of bevacizumab for the treatment of ovarian cancer relatedresearch progress were reviewed.